rs755184077

Variant summary

Our verdict is Likely pathogenic. The variant received 9 ACMG points: 9P and 0B. PVS1PP5

The NM_020810.3(TRMT5):​c.312_315delAATA​(p.Ile105SerfsTer4) variant causes a frameshift change. The variant allele was found at a frequency of 0.000902 in 1,614,150 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: 𝑓 0.00082 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00091 ( 0 hom. )

Consequence

TRMT5
NM_020810.3 frameshift

Scores

Not classified

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:6U:3

Conservation

PhyloP100: 6.82

Publications

7 publications found
Variant links:
Genes affected
TRMT5 (HGNC:23141): (tRNA methyltransferase 5) tRNAs contain as many as 13 or 14 nucleotides that are modified posttranscriptionally by enzymes that are highly specific for particular nucleotides in the tRNA structure. TRMT5 methylates the N1 position of guanosine-37 (G37) in selected tRNAs using S-adenosyl methionine (Brule et al., 2004 [PubMed 15248782]).[supplied by OMIM, Mar 2008]
TRMT5 Gene-Disease associations (from GenCC):
  • mitochondrial disease
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • combined oxidative phosphorylation defect type 26
    Inheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_pathogenic. The variant received 9 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 14-60979582-CTATT-C is Pathogenic according to our data. Variant chr14-60979582-CTATT-C is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 372246.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TRMT5NM_020810.3 linkc.312_315delAATA p.Ile105SerfsTer4 frameshift_variant Exon 2 of 5 ENST00000261249.7 NP_065861.3 Q32P41
TRMT5NM_001350253.1 linkc.396_399delAATA p.Ile133SerfsTer4 frameshift_variant Exon 2 of 5 NP_001337182.1
TRMT5NM_001350254.1 linkc.393_396delAATA p.Ile132SerfsTer4 frameshift_variant Exon 2 of 5 NP_001337183.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TRMT5ENST00000261249.7 linkc.312_315delAATA p.Ile105SerfsTer4 frameshift_variant Exon 2 of 5 1 NM_020810.3 ENSP00000261249.6 Q32P41
TRMT5ENST00000553903.1 linkc.396_399delAATA p.Ile133SerfsTer4 frameshift_variant Exon 2 of 2 4 ENSP00000452567.1 G3V5X1
TRMT5ENST00000555420.1 linkc.393_396delAATA p.Ile132SerfsTer4 frameshift_variant Exon 2 of 2 4 ENSP00000451666.1 G3V494
ENSG00000258892ENST00000553946.1 linkn.123-2924_123-2921delATTT intron_variant Intron 1 of 1 5

Frequencies

GnomAD3 genomes
AF:
0.000821
AC:
125
AN:
152164
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000121
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000589
Gnomad ASJ
AF:
0.00346
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000415
Gnomad FIN
AF:
0.000283
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00135
Gnomad OTH
AF:
0.000955
GnomAD2 exomes
AF:
0.000867
AC:
218
AN:
251378
AF XY:
0.000979
show subpopulations
Gnomad AFR exome
AF:
0.0000615
Gnomad AMR exome
AF:
0.000347
Gnomad ASJ exome
AF:
0.00337
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000231
Gnomad NFE exome
AF:
0.00130
Gnomad OTH exome
AF:
0.000815
GnomAD4 exome
AF:
0.000910
AC:
1331
AN:
1461868
Hom.:
0
AF XY:
0.000873
AC XY:
635
AN XY:
727226
show subpopulations
African (AFR)
AF:
0.0000896
AC:
3
AN:
33480
American (AMR)
AF:
0.000268
AC:
12
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00291
AC:
76
AN:
26134
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39696
South Asian (SAS)
AF:
0.000383
AC:
33
AN:
86254
European-Finnish (FIN)
AF:
0.000206
AC:
11
AN:
53416
Middle Eastern (MID)
AF:
0.000693
AC:
4
AN:
5768
European-Non Finnish (NFE)
AF:
0.00102
AC:
1132
AN:
1112000
Other (OTH)
AF:
0.000993
AC:
60
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.477
Heterozygous variant carriers
0
82
165
247
330
412
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
32
64
96
128
160
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000821
AC:
125
AN:
152282
Hom.:
0
Cov.:
32
AF XY:
0.000712
AC XY:
53
AN XY:
74450
show subpopulations
African (AFR)
AF:
0.000120
AC:
5
AN:
41562
American (AMR)
AF:
0.000589
AC:
9
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.00346
AC:
12
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5186
South Asian (SAS)
AF:
0.000415
AC:
2
AN:
4820
European-Finnish (FIN)
AF:
0.000283
AC:
3
AN:
10604
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00135
AC:
92
AN:
68028
Other (OTH)
AF:
0.000945
AC:
2
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.493
Heterozygous variant carriers
0
8
16
23
31
39
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000473
Hom.:
0
Bravo
AF:
0.000733
EpiCase
AF:
0.00153
EpiControl
AF:
0.00142

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:6Uncertain:3
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Pathogenic:2Uncertain:2
Sep 14, 2023
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is not a known mechanism of disease; This variant is associated with the following publications: (PMID: 34426522, 31038196, 26189817, 29021354, 35342985) -

Oct 24, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change creates a premature translational stop signal (p.Ile105Serfs*4) in the TRMT5 gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in TRMT5 cause disease. This variant is present in population databases (rs755184077, gnomAD 0.3%), and has an allele count higher than expected for a pathogenic variant. This premature translational stop signal has been observed in individual(s) with features of combined oxidative phosphorylation deficiency (PMID: 26189817, 29021354). ClinVar contains an entry for this variant (Variation ID: 372246). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Jan 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

TRMT5: PS4, PM4 -

Jul 24, 2017
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Combined oxidative phosphorylation defect type 26 Pathogenic:3
Jun 01, 2022
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

May 15, 2023
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

- -

Apr 27, 2023
Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL)
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

- -

TRMT5-related disorder Pathogenic:1
Sep 26, 2024
PreventionGenetics, part of Exact Sciences
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

The TRMT5 c.312_315delAATA variant is predicted to result in a frameshift and premature protein termination (p.Ile105Serfs*4). This variant was previously described in the presumably compound heterozygous state in two unrelated individuals who presented with combined oxidative phosphorylation deficiency (Powell et al. 2015. PubMed ID: 26189817), and in the compound heterozygous state in two affected sisters from a different family (Tamopolsky et al. 2017. PubMed ID: 29021354). The c.312_315del variant has a relatively high minor allele frequency (~0.33%) in at least one sub-population in a large population database, but no homozygotes were described in the same database. Frameshift variants in TRMT5 are expected to be pathogenic. This variant is classified as likely pathogenic. -

not specified Uncertain:1
Mar 01, 2024
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: TRMT5 c.312_315delAATA (p.Ile105SerfsX4) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The tRNA methyltransferase 5 (TRMT5) gene encodes a protein involved in methylation of a specific nucleotide (position 37) adjacent to the anticodon of mitochondrial-tRNA molecules to enhance their translational efficiency/fidelity (Tarnopolsky_2017). The p.Ile105Serfs*4 frameshift mutation is upstream of the methyltransferase motif, therefore it is predicted to result in a truncated protein that is expected to be non-functional (Powell_2015). The variant allele was found at a frequency of 0.00087 in 251378 control chromosomes, predominantly at a frequency of 0.0013 within the Non-Finnish European subpopulation in the gnomAD database. As the prevalence of Combined Oxidative Phosphorylation Defect Type 26 and attributable risk of TRMT5 gene and variants cannot be estimated, this frequency does not allow conclusions about variant significance. c.312_315delAATA has been reported in the literature as a compound heterozygous genotype with other TRMT5 missense variants in trans in at least seven probands from six separate families presenting with varying clinical features, suggestive of mitochondrial disease (e.g., Powell_2015, Tarnopolsky_2017, Argente-Escrig_2022). Each of these probands were comprehensively evaluated to rule out other genetic conditions prior to whole exome sequencing (WES). It has also been reported as a non-informative genotype (zygosity/genotype not specified) in an autistic proband who underwent whole genome sequencing (e.g., Callaghan_2019) but has not been considered as a relevant correlation in the context of this evaluation. These data indicate that the variant might be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. ClinVar contains an entry for this variant (Variation ID: 372246). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
PhyloP100
6.8
Mutation Taster
=5/195
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs755184077; hg19: chr14-61446300; COSMIC: COSV109406877; COSMIC: COSV109406877; API